|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues, net | |||||
| Cost of revenues | |||||
| Gross profit | |||||
| Operating expense: | |||||
| General and administrative | |||||
| Depreciation and amortization | |||||
| Research and development | |||||
| Impairment of goodwill | |||||
| Total operating expense | |||||
| Loss from operations | |||||
| Other (expense) income: | |||||
| Interest expense, net | |||||
| Other income (expense), net | |||||
| Gain on settlement of liabilities, net | |||||
| Loss on warrant issuance | |||||
| Change in fair value of derivative liabilities | |||||
| Nonrelated Party | |||||
| Related Party | |||||
| Total change in fair value of derivative liabilities | |||||
| Change in fair value of common warrants | |||||
| Total other expense | |||||
| Loss before income taxes | |||||
| Income tax benefit | |||||
| Net loss | |||||
| Other comprehensive loss: | |||||
| Foreign currency translation adjustment | |||||
| Total comprehensive loss | |||||
| Net loss per common share – basic (in dollars per share) | |||||
| Net loss per common share – diluted (in dollars per share) | |||||
| Weighted average number of common shares outstanding – basic (in shares) | |||||
| Weighted average number of common shares outstanding – diluted (in shares) | |||||
| Fixed dividends - Series B Preferred | |||||
| Net loss attributable to common stockholders - basic | |||||
| Net loss attributable to common stockholders - diluted | |||||
Loading...